Integrative Analysis of Human Glioblastoma Multiforme
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Normal brain tissue.
- Who it may be relevant to
- Registry conditions: GBM. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Integrative analysis of GBM
Detailed description
The investigators will analyzed proteomes of paired normal brain tissues and GBM, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal brain tissue, primary GBM carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of GBM characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.
Interventions
- Other Normal brain tissue
The investigators will extract total protein, DNA and RNA from the samples.
Primary outcome measures
- 5 years overall survival [Time frame: 5 years]
Secondary outcome measures (3)
- 5 years disease-free survival [Time frame: 5 years]
- 10 years overall survival [Time frame: 10 years]
- 10 years disease-free survival [Time frame: 10 years]
Eligibility criteria
Inclusion criteria
- Age ≤ 75 years with histologically proven GBM
- No severe major organ dysfunction
- World Health Organization (WHO) performance status of 0 or 1
- No prior cancer chemotherapy
Exclusion criteria
- Age ≥ 76
- Severe major organ dysfunction
- WHO performance status of >1
- Prior cancer chemotherapy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-control
Study locations
China · 1 center
- Shanghai Tenth People's Hospital — Shanghai
Publications
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4. PMID 25651787
Identifiers
NCT: NCT03005132 · 2016-521-Rainy